Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Predictors for Response to Dose-dense Docetaxel and Epirubicin Breast Cancer (MEDOBREC)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Haukeland University Hospital
Information provided by (Responsible Party):
Per Eystein Lonning, University of Bergen
ClinicalTrials.gov Identifier:
NCT00496795
First received: July 3, 2007
Last updated: May 18, 2016
Last verified: May 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: May 2026
  Primary Completion Date: May 2016 (Final data collection date for primary outcome measure)